Registrieren Sie sich, um Meldungen für Instrumente,
Wirtschaftsevents und Inhalte von Autoren zu erhalten, denen Sie folgen
Kostenlose Registrierung Sie haben bereits ein Benutzerkonto? Anmelden
Kurse
Alle Finanzinstrumente
- Alle Finanzinstrumente
- Indizes
- Aktien
- ETFs
- Fonds
- Rohstoffe
- Währungen
- Krypto
- Anleihen
- Zertifikate
Versuchen Sie es noch einmal mit einem anderen Suchbegriff
👀 👁 🧿 Biogen: +4,56% nach Quartalszahlen. Unsere KI erkannte das Potenzial bereits im März 2024.
Welche Aktie wird als nächstes durchstarten?
Welche Aktie wird als nächstes durchstarten?
Jetzt Aktien finden
T. Rowe Price Health Sciences Fund (PRHSX)
Einem Portfolio hinzufügen/entfernen
Portfolio hinzufügen
89,79
+0,29
+0,32%
- Morningstar Rating:
- Fondsvermögen: 8,79B
T. Rowe Price Health Sciences
89,79
+0,29
+0,32%
- Allgemein
- Chart
- Nachrichten & Analysen
- Technisch
- Forum
PRHSX Übersicht
Auf dieser Seite finden Sie ein ausführliches T. Rowe Price Health Sciences Fund Profil. Erfahren Sie mehr über das Management, das Gesamtvermögen, die Anlagestrategie und die PRHSX Kontaktinformationen.
Kontaktinformation
Adresse
The Gate, Level 15, Office 24
Dubai,Dubai XXXXXX
United Arab Emirates
Dubai,Dubai XXXXXX
United Arab Emirates
Telefon
97 14 401 9266
Management
| Name | Titel | Seit | Bis |
|---|---|---|---|
| Ziad Bakri | Equity Research Analyst | 2016 | Aktuell |
| Biografie | Ziad Bakri joined T. Rowe Price in 2011 and has since been a key member of the healthcare research team, influencing investment decisions and making significant contributions to the stock selections. Ziad has had a long track record of analyzing biotechnology companies, a key sector within the healthcare industry. Ziad brings a unique perspective to his new role, having been a medical doctor and an emergency medicine resident at the Royal London Hospital before beginning his investment career. Prior to joining T. Rowe Price, Ziad held biotechnology equity research and healthcare investment ban | ||
| Taymour R. Tamaddon | Portfolio Manager | 2013 | 2016 |
| Biografie | Taymour R. Tamaddon is a vice president of T. Rowe Price Group, Inc. and T. Rowe Price Associates, Inc. He is also a vice president of the T. Rowe Price Institutional International Funds, Inc., and the T. Rowe Price International Funds, Inc. He joined the firm in 2004 after serving as a summer intern with T. Rowe Price in 2003, covering the eye care industry. Prior to this, Taymour was employed by Amazon.com in the areas of finance and merchandizing. He was also a consultant with Booz Allen and Hamilton, specializing in the energy industry. | ||
| Kris H. Jenner | Chairman | 2000 | 2013 |
| Biografie | Mr. Jenner has been chairman of the committee since2000.He is a lead portfolio manager and a VP of T. Rowe Price Group. Dr. Jenner joined T. Rowe in 1997 as a health care sector analyst and now acts as its lead analyst for biotechnology and US pharmaceutical companies. He has also been portfolio manager for the Oxford Capital Group, where he managed a private hedge fund specializing in health care. Dr. Jenner graduated summa cum laude and as a member of Phi Beta Kappa from the University of Illinois with a B.S. in Chemistry. He received a D. Phil. from University of Oxford. | ||
| Laurie Mundt | Research Analyst | 2007 | 2007 |
| Biografie | Prior to joining Fidelity Investments in 2008 as a research analyst, Ms. Mundt served as a vice president for T. Rowe Price Group, which she joined in 2000. | ||
| Brian Stansky | Vice President, Investment Analyst | 1998 | 2000 |
| Biografie | Stansky is a vice president with T. Rowe Price Associates, his employer since 1989. He also serves as an investment analyst in the firm's equity research division. Previously, he worked as a financial analyst with Honeywell Information Systems. Stansky is a Chartered Financial Analyst. | ||
| Joseph Klein | Vice President | 1995 | 1998 |
| Biografie | Joseph Klein is a Portfolio Manager for the Hightower Equity SMA strategies. He is responsible for the quantitative modeling and leads portfolio construction decisions made throughout the investment process. Joe has seven years of investment related experience and was previously a Leveraged Finance Credit Analyst for Barclays, where he covered health care and industrial companies. Joe also spent time as a Restructuring Senior Associate for Ankura Consulting Group, where he advised the Government of Puerto Rico in 2017-2018. Joe graduated from New York University’s Stern School of Business. Joe holds the FINRA Series 7 & 63 licenses. Outside of work, Joe interests include real estate, softball, and urban gardening. He is a lifelong New Yorker. | ||
Was denken Sie über T. Rowe Price Health Sciences Fund
Sind Sie sicher, dass Sie diesen Chart löschen möchten?
Löschen Abbrechen
Angehängten Chart durch einen neuen Chart ersetzen?
Ersetzen Abbrechen
Community-Richtlinien
Chart zum Kommentar hinzufügen
Sperre bestätigen
Sind Sie sicher, dass Sie %USER_NAME% sperren möchten?
Dadurch werden Sie und %USER_NAME% nicht mehr in der Lage sein, Beiträge des jeweils anderen auf Investing.com zu sehen.
%USER_NAME% wurde erfolgreich zu Ihrer Sperrliste hinzugefügt.
Da Sie diese Person entsperrt haben, müssen Sie 48 Stunden warten, bevor Sie sie wieder sperren können.
Diesen Kommentar melden
Sagen Sie uns Ihre Meinung zu diesem Kommentar
Kommentar markiert
Vielen Dank!
Ihre Meldung wurde zur Überprüfung an unsere Moderatoren geschickt